Clinical Trial

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, exploratory study. People with recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for ovarian cancer were selected to evaluate the efficacy and safety of adebrelimab combined with fuzuloparib.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-23; most recent amendment 2024-02-04.
Status change: Not Yet Recruiting → Recruiting 2023-10-17
Trial Details
NCT Number NCT05753826
Lead Sponsor Fujian Cancer Hospital
Conditions Ovarian Neoplasms, Ovarian Diseases
Enrollment 37 participants
Start Date 2023-08-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-02-06